07 September 2019 : Case report
Humoral Hypercalcemia in a Patient with Cholangiocellular Carcinoma – Effective Therapy with Denosumab
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Educational Purpose (only if useful for a systematic review or synthesis)Igor Alexander Harsch1ABCE*, Peter Christopher Konturek2CEF
Am J Case Rep 2019; 20:1325-1330
BACKGROUND: Hypercalcemia in cholangiocellular carcinoma is a highly uncommon event, mainly reported in Asian patients. In the absence of bone metastases, humoral hypercalcemia of malignancy (HHM) can be assumed. This is mostly the consequence of an elevated parathormone-related peptide (PTHrP) level. The standard therapeutic options in HHM are sometimes limited by the underlying disease or concomitant diseases.
CASE REPORT: We report the case of a 65-year-old Caucasian male. A syncope due to a hypercalcemia of 4.16 mmol/L (normal range, 2.19–2.54 mmol/L) was the initial symptom that eventually led to the diagnosis of cholangiocellular carcinoma. He had no metastatic bone disease; HHM was suspected. PTHrP was moderately elevated. Since there were contraindications for the standard therapeutic options, a therapy with 120 mg denosumab was initiated and proved effective, safe, and restored the patient’s quality of life for 11 months.
CONCLUSIONS: The moderate elevation of parathyroid hormone-related peptide (PTHrP) in this case is addressed in context with the recent insights of a substantial underestimation of this parameter by many commercial assays which can explain our observation. Denosumab, a human monoclonal antibody which acts as a RANKL-inhibitor (receptor activator of nuclear factor kappaB ligand) was recently suggested as a therapeutic alternative. In this case, the therapy of the hypercalcemia with denosumab due to contraindications for other therapies led to an effective and long-standing remission of hypercalcemia. Its effectivity should be studied in larger case samples.
Keywords: Cholangiocarcinoma, Hypercalcemia, Parathyroid Hormone, Bile Duct Neoplasms, Bone Density Conservation Agents, denosumab, Paraneoplastic Syndromes, Parathyroid Hormone-Related Protein, Syncope
01 Feb 2024 : Case reportConservative versus Surgical Treatment of Pneumatosis Intestinalis: Experience from a Multidisciplinary Center
Am J Case Rep In Press; DOI: 10.12659/AJCR.943166
08 Feb 2024 : Case reportRight Thigh Mass Metastasis from Lung Cancer Mimicking Primary Soft Tissue Sarcoma: A Case Report
Am J Case Rep In Press; DOI: 10.12659/AJCR.942416
05 Feb 2024 : Case reportUnraveling the Uncommon: A Case Report of Giant Cell Myocarditis and Examination of Existing Literature
Am J Case Rep In Press; DOI: 10.12659/AJCR.942381
Most Viewed Current Articles
10 Jan 2022 : Case reportA Report on the First 7 Sequential Patients Treated Within the C-Reactive Protein Apheresis in COVID (CACOV...
Am J Case Rep 2022; 23:e935263
19 Jul 2022 : Case reportAtlantoaxial Subluxation Secondary to SARS-CoV-2 Infection: A Rare Orthopedic Complication from COVID-19
Am J Case Rep 2022; 23:e936128
05 Mar 2022 : Case reportAcute Limb Ischemia After Self-Injection of Crushed Morphine Tablets into the Radial Artery: Role of Infrar...
Am J Case Rep 2022; 23:e935336